Infinity Pharmaceuticals Inc. (NASDAQ:INFI) major shareholder Value Fund L. P. Biotechnology bought 100,000 shares of the business’s stock in a transaction on Wednesday, November 28th. The shares were acquired at an average cost of $1.30 per share, for a total transaction of $130,000.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
NASDAQ INFI opened at $1.33 on Monday. Infinity Pharmaceuticals Inc. has a one year low of $1.22 and a one year high of $2.92.
Infinity Pharmaceuticals (NASDAQ:INFI) last posted its earnings results on Monday, November 5th. The biotechnology company reported $0.23 EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.37. The business had revenue of $22.00 million for the quarter. As a group, research analysts expect that Infinity Pharmaceuticals Inc. will post -0.23 earnings per share for the current year.
A number of research analysts have commented on the stock. Wells Fargo & Co downgraded shares of Infinity Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Monday, November 12th. JPMorgan Chase & Co. downgraded shares of Infinity Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research report on Monday, November 12th. Finally, Zacks Investment Research downgraded shares of Infinity Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 9th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $3.50.
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.
Further Reading: Swap
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.